Recently stock market analysts have updated their consensus ratings on shares of Blueprint Medicines Corporation (NASDAQ:BPMC).

Most recent broker ratings

03/09/2016 – Blueprint Medicines Corporation had its “market outperform” rating reiterated by analysts at JP Morgan. They now have a USD 37 price target on the stock.

07/14/2015 – Blueprint Medicines Corporation had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 41 price target on the stock.

07/13/2015 – Blueprint Medicines Corporation had its “buy” rating reiterated by analysts at Cowen.

05/26/2015 – JMP Securities began new coverage on Blueprint Medicines Corporation giving the company a “market outperform” rating. They now have a USD 54 price target on the stock.

05/26/2015 – Goldman Sachs began new coverage on Blueprint Medicines Corporation giving the company a “neutral” rating. They now have a USD 26 price target on the stock.

Blueprint Medicines Corporation has a 50 day moving average of 17.63 and a 200 day moving average of 19.43. The stock’s market capitalization is 369.91M, it has a 52-week low of 13.04 and a 52-week high of 37.17.

The share price of the company (NASDAQ:BPMC) was down -1.80%, with a high of 14.16 during the day and the volume of Blueprint Medicines Corporation shares traded was 82021.

View other investors thoughts on Blueprint Medicines Corporation with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.